PubMed Health⌕ Search

Biomedical subjects

Miro Morović

Publications and source records attributed to Miro Morović.

2 recordsLinked to original sources

[Viral hepatitis: Croatian consensus statement].

There has been a dramatic improvement in diagnostic procedures and therapy of viral hepatitis in the last 20 years. Improvements in therapy caused an increase in actual cost, however, with significant long-term savings through a decreased cost of treatment of advanced liver disease including liver transplantation. The Croatian National Board for Viral Hepatitis has decided to initiate the organization of consensus conference on viral hepatitis enabling the leading experts in the country to give the best possible recommendations for the diagnosis, prophylaxis and therapy in our circumstances. The Consensus Conference took place in Zagreb in June 2004, with update in March 2005, organized by the Croatian National Board for Viral Hepatitis, Reference Centers of the Ministry of Health for Chronic Liver Diseases, Infectious Diseases and AIDS, Croatian Society of Gastroenterology--Hepatology Section, Croatian Society for Nephrology, Dialysis and Transplantation, and Croatian Institute for Health Insurance. Invited experts provided written reports on the respective subjects that appear in this issue and their recommendations resulting in this consensus statement.

Consensus Statements as Topic↗

[Treatment of chronic hepatitis B].

More that 350 million people worldwide suffer from chronic hepatitis B virus (HBV) infection. Up to 40 percent of persons infected with the virus may develop complications related to cirrhosis or hepatocellular carcinoma. This reservoire is further growing up despite the fact that more than 110 countries have introduced large-scale vaccination against hepatitis B as part of the worldwide campaign launched by the WHO in 1991 and despite improved blood supply testing. At present, in Croatia there are no precise data on the rate of chronic HBV carriers, however, it is estimated to be < 2% (low prevalence country). To date, two drugs, interferon alfa and lamivudine, have been approved for the treatment of chronic hepatitis B in Croatia. Recent guidelines for the treatment of chronic hepatitis B based on the accumulated knowledge on the disesase pathogenesis and treatment outcome are presented.

Antiviral Agents↗